12.17  1.53 (14.38%)		01-23 16:00
Open: 10.55 High: 12.25 Volume: 1,826,287		Pre. Close: 10.64 Low: 10.486 Market Cap: 623(M)

Short term
Mid term
Targets	6-month :	14.3	1-year :	16.71
Resists	First :	12.25	Second :	14.3
Pivot price	9.14
Supports	First :	9.35	Second :	7.57
MAs	MA(5) :	10.11	MA(20) :	9.15
	MA(100) :	7.78	MA(250) :	5.74
MACD	MACD :	0.5	Signal :	0.2
%K %D	K(14,3) :	92.2	D(3) :	80.8
RSI	RSI(14): 77.8
52-week	High :	12.25	Low :	2.65

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ENGN ] has closed It is unclear right now based on current values. 59% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	12.26 - 12.31	12.31 - 12.36
Low:	10.38 - 10.43	10.43 - 10.48
Close:	12.08 - 12.17	12.17 - 12.25

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Fri, 23 Jan 2026
enGene extends momentum with another 14% surge on Friday (ENGN:NASDAQ) - Seeking Alpha

Fri, 23 Jan 2026
enGene (NASDAQ:ENGN) Hits New 1-Year High - Still a Buy? - MarketBeat

Thu, 22 Jan 2026
enGene (NASDAQ:ENGN) Stock Price Up 11.3% - Time to Buy? - MarketBeat

Wed, 21 Jan 2026
enGene (NASDAQ:ENGN) Sees Strong Trading Volume - What's Next? - MarketBeat

Wed, 21 Jan 2026
enGene Holdings (NASDAQ: ENGN) adds $125M debt facility and new warrants - Stock Titan

Tue, 20 Jan 2026
enGene Holdings Secures $125 Million Loan Agreement with Hercules Capital - Intellectia AI

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	67 (M)
Shares Float	33 (M)
Held by Insiders	0 (%)
Held by Institutions	77.9 (%)
Shares Short	1,500 (K)
Shares Short P.Month	1,140 (K)

EPS	-2.29
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.22
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-28.9 %
Return on Equity (ttm)	-53.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.84
Qtrly Earnings Growth	0 %
Operating Cash Flow	-99 (M)
Levered Free Cash Flow	-60 (M)

PE Ratio	-5.32
PEG Ratio	0
Price to Book value	3.77
Price to Sales	0
Price to Cash Flow	-8.22

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.